{"id":"177lu-fap-2286","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Vomiting"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"5-15%","effect":"Anemia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Neutropenia"}]},"_chembl":{"chemblId":"CHEMBL3707297","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by selectively binding to FRα, which is overexpressed in certain types of cancer cells, allowing for targeted radiation therapy. This approach aims to minimize damage to healthy tissues while maximizing the therapeutic effect on cancer cells.","oneSentence":"177Lu-FAP-2286 is a radiolabeled antibody that targets folate receptor alpha (FRα) for the treatment of cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:19:10.534Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory follicular lymphoma"},{"name":"Relapsed or refractory diffuse large B-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT04939610","phase":"PHASE1, PHASE2","title":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-30","conditions":"Solid Tumor","enrollment":222},{"nctId":"NCT07434180","phase":"PHASE2","title":"Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary","status":"NOT_YET_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2026-06","conditions":"Cancer of Unknown Primary","enrollment":20},{"nctId":"NCT06880757","phase":"PHASE2","title":"177Lu-FAP-2286 Treatment in Urethelial Neoplasms: Utility and Safety as a Novel Treatment.","status":"NOT_YET_RECRUITING","sponsor":"Ankara University","startDate":"2025-06-01","conditions":"Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"177Lu-FAP-2286","genericName":"177Lu-FAP-2286","companyName":"Peter MacCallum Cancer Centre, Australia","companyId":"peter-maccallum-cancer-centre-australia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"177Lu-FAP-2286 is a radiolabeled antibody that targets folate receptor alpha (FRα) for the treatment of cancer. Used for Relapsed or refractory follicular lymphoma, Relapsed or refractory diffuse large B-cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}